BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 05-08-2025: Outcome of Board Meeting

Balaxi Pharmaceuticals' board approved the consolidated financial results for the quarter ended June 30, 2025. Revenue from operations stood at Rs 70.74 Cr, with a net profit of Rs 0.29 Cr. Significant progress on their Jadcherla, Hyderabad plant: all installation, operational, and performance qualifications are complete. Water validation and vendor qualification are set to conclude by August end, with manufacturing test license already secured. Stability batch production is expected to begin early September. Further strengthening its footprint, the company's subsidiary Balaxi Global DMCC acquired Balaxi Healthcare Nicaragua.